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introduction: Drug-resistant cluster headache (CH) is still an open clinical challenge. 
Recently, our group observed the clinical efficacy of a ketogenic diet (KD), usually 
adopted to treat drug-resistant epilepsies, on migraine.
aim: Here, we aim to detect the effect of KD in a group of drug-resistant chronic CH 
(CCH) patients.
Materials and methods: Eighteen drug-resistant CCH patients underwent a 12-week 
KD (Modified Atkins Diet, MAD), and the clinical response was evaluated in terms of 
response (≥50% attack reduction).
results: Of the 18 CCH patients, 15 were considered responders to the diet (11 expe-
rienced a full resolution of headache, and 4 had a headache reduction of at least 50% in 
terms of mean monthly number of attacks during the diet). The mean monthly number of 
attacks for each patient at the baseline was 108.71 (SD = 81.71); at the end of the third 
month of diet, it was reduced to 31.44 (SD = 84.61).
conclusion: We observed for the first time that a 3-month ketogenesis ameliorates 
clinical features of CCH.
clinical Trial registration: www.ClinicalTrials.gov, identifier NCT03244735.
Keywords: ketogenic diet, modified atkins diet, ketogenesis, ketone bodies, cluster headache, drug resistance
inTrODUcTiOn
Cluster headache (CH) is characterized by unilateral trigeminovascular and autonomic system co-
activation. The headaches (0.5–8 attacks per day, lasting 15–180 min) persist for weeks or months 
(bout), followed by a complete remission until the start of the next cluster of attacks. If patients 
have no remission periods, their CH is defined as chronic (CCH) in contrast to the episodic form 
(ECH) (1).
Chronic CH remains an open challenge for clinicians; several patients are drug resistant or 
unsatisfied by current treatments. They, looking for relief, may abandon the medical care and resort 
to alternative medicines or illicit substances (2).
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Our group has observed migraine patients’ headache relief 
following a ketogenic diet (KD) (3), a nutritional regime usually 
adopted to treat drug-resistant epilepsies. Afterward, we have 
prescribed the KD to a migraine patient also affected by drug-
resistant CCH and, surprisingly, both headaches responded to 
the diet. Since some of the mechanisms supposed to be the target 
of the KD in migraine are shared with CH (such as activation 
of the trigeminal nerve in mediating pain and monoaminergic 
involvement) (4), it is of interest to explore whether a KD inter-
vention is effective as a prophylactic treatment for CH. In this 
open-label study, we therefore aimed to assess the efficacy and the 
safety of KD in patients with drug-resistant CCH.
MaTerials anD MeThODs
study Design
A prospective, open-label, single-arm clinical trial.
Participants
This case series was conducted with the support of the Italian 
branch of the Organisation for the Understanding of Cluster 
Headache (OUCH-Italia), which referred to us chronic patients 
who abandoned the medical care but wished to try the KD. Our 
local Ethics Committee gave approval for the study, and writ-
ten informed consent was obtained from all the participants. 
The trial was registered on ClinicalTrials.gov (NCT03244735). 
Patients received information about the diet and were asked to 
complete a headache diary (attack frequency and name/number 
of acute headache medication) for 1 month before the start of the 
diet and during the 12-week study period.
The inclusion criteria were diagnosis of CCH according to 
the ICHD-3 beta criteria (1) and abandonment of previous drug 
prophylactic treatments (see Results).
The exclusion criteria were regular extra-headache medication 
intake (i.e., antibiotics, corticosteroids, antidepressants, benzodi-
azepines, and illicit drugs) except for hormonal contraceptives, 
history of other neurological diseases, connective or autoimmune 
diseases, and any other type of primary or secondary headaches. 
Moreover, for uniformity in the dietetic intervention, we excluded 
over-weight and obese patients who were referred to a different 
dietetic regime. Female participants were informed that in case of 
pregnancy they should drop out of the study. All study participants 
were unfamiliar with the KD and received a complete descrip-
tion of the study and gave informed consent. The project was 
approved by the Ethics Committee of the “Sapienza” University 
of Rome, Polo Pontino and was compliant with the Committee on 
Publication Ethics and the International Committee of Medical 
Journal Editors recommendations for ethics.
The responder rate (≥50% reduction of attack frequency) was 
calculated. Patients were interviewed about adverse events at each 
monthly visit. An explorative statistical analysis with repeated 
measures Analysis of Variance (rm-ANOVA) model was adopted to 
detect differences between the baseline and the other months of diet.
Modified atkins Diet
Patients were administered a 12-week ketogenic dietary regime 
[modified Atkins diet (MAD)] (5) consisting of low carbohydrate 
(about 15 g/day), normal/low protein (about 0.7–1.2 g/kg/day), 
and high fat (approximately little more than the weight of carbo-
hydrates and proteins together) from meals prepared by common 
foods. To summarize, no more than 10 g of carbohydrates per 
day are allowed in the first month (after that, up to 20–30 g/day) 
subdivided into three regular-size meals a day or four to five 
smaller meals. Each meal consists of a liberal combination of 
fat and protein in the form of fish, shellfish, poultry, red meat, 
eggs, or low-carbohydrate and high-fat cheese, dressed with 
butter, heavy whipping cream, mayonnaise, olive oil, and other 
vegetable oils. Almonds, nuts, and oilseeds are suitable as snack. 
Salad vegetable twice per day, dressed with oil, mayonnaise or 
sour cream, vinegar (without added sugars, no balsamic), and 
salt. Leafy vegetables, up to 200 g per portion. Other vegetables 
are limited. All spices to add taste (without added sugar) are 
allowed. Patients must avoid rice, grains, cereals and derivate 
(bread, pasta, crackers, cookies, etc.), legumes, starchy veg-
etables (potatoes, corn, green peas), fruits, and dairy products 
other than cheese, cream, or butter. The exact amount of food 
per day was suggested to each patient according to their caloric 
needs (as determined by dietician), but patients could adjust the 
quantity of foods if required by their sense of satiety/appetite. 
The caloric intake was possibly adjusted according to patients’ 
caloric needs, with lipids in the form of a powder composed 
of medium chain triglycerides, as well as omega-3, and long 
chain triglycerides (Ketoneural Lipid Complex, Medi-Diet s.r.l., 
Aprilia, Italy) with nutraceutical integrators (3). Patients were 
advised to drink 2–2.5  l of water per day. A daily urine stick 
test confirmed the presence of ketogenesis. Patients reported in 
the diary each attack, the use of symptomatic treatments, and 
any eventual side effects or adverse events related to the diet 
(Appendix S1 in Supplementary Material). Moreover, they had 
medical supervision for every 4  weeks and laboratory blood 
tests (alanine aminotransferase, aspartate aminotransferase, 
gamma glutamic transpeptidase, lactic dehydrogenase, alkaline 
phosphatase, bilirubin, blood urea nitrogen, and creatinine) at 
the start and end of the 12-week KD.
resUlTs
Organisation for the Understanding of Cluster Headache-Italia 
referred 30 patients to us, of which 19 had CCH, 11 were episodic, 
and thus excluded from the survey. Out of 19 CCH patients, 18 
(11 males; 7 females) elected to take part in the diet after they 
received explanations and completed the 1-month headache 
diary. Demographics information and headache characteristics 
are given in Table  1. The previous prophylactic treatments 
(reported to be ineffective or not tolerated) included verapamil 
(240–1,080 mg/day) and lithium (up to 900 mg/day) alone or in 
combination with other treatments such as sodium valproate (up 
to 1,200 mg/day), topiramate (up to 400 mg/day), gabapentin (up 
to 1,600 mg/day), amitriptyline (up to 75 mg/day), and various 
corticosteroids. Each patient had previously tried at least three 
different prophylaxis drugs.
Of the 18 CCH patients, 15 were considered responders: 11 
experienced a full resolution of headache (6 patients in the first 
4 weeks, 2 patients in 8 weeks, and 3 patients in 12 weeks) and 
FigUre 1 | Number of attacks during the diet in 18 chronic cluster 
headache patients. Circles indicate the mean number of attacks per  
month at the baseline and during the 3 months of diet; bars indicate the 
SEM.
Table 1 | Sociodemographic and clinical characteristics of 18 chronic cluster 
headache (CH) patients.
Patient 
iD
age ch 
duration
chronic 
from
attacks for months
baseline Diet month
1st 2nd 3rd
1 26 4 4 63 3 0 0
2 51 22 12 210 208 118 5
3 44 19 7 121 110 58 0
4 39 8 3 59 2 0 0
5 25 6 2 30c 2 0 0
6 41 15 5 100 59 28 0
7 47 20 7 211b 148 90 10
8 37 8 2 122 61 29 0
9 40 21 5 61 4 0 0
10 30 5 2 30 2 0 0
11 55 30 15 120 58 29 14
12 26 9 3 62 60 59 61
13 42 12 5 93 88 17 28
14 44 22 12 121 63 3 0
15 29 14 9 32 2 0 0
16 45 15 3 91 7 88 93
17 36 8 4 63 4 0 0
18 28 6 6 358b 340 360 355
Mean 25–55a 13.56 5.89 108.17 67.83 48.83 31.44
SD 7.43 3.83 81.71 89.45 86.11 84.61
CH duration = duration in years of CH from the first episode.
Chronic from = duration in years of chronification of CH.
aRange of ages.
bTwo patients had more than eight attacks per day occasionally (#7) or daily (#18). 
They reported that the number of attacks increases as a consequence of the use of 
sumatriptan s.c. that determined a sort of “shift effect” of attacks (sudden remission of 
the pain and recurrence within a few hours). Even if it is in contrast to the classification 
criteria (they apparently could be regarded as paroxysmal hemicrania patients), the 
response to CH symptomatic therapies (oxygen and sumatriptan) and the lack of 
response to indomethacin (specific for paroxysmal hemicranias) allowed us to confirm 
the diagnosis of CH and consider the higher frequency of attacks as a sign of a drug-
induced transformation.
cOne patient (#5) experienced attacks with durations >180 min (≅240 min). According 
to the classification, this patient can be classified as 3.5.1 probable CH.
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4 had a headache reduction of at least 50% in terms of mean 
monthly number of attacks. Of the three non-responders, two had 
no response within the 12-week diet period; one experienced an 
early response, but had difficulties in maintaining the ketosis for 
repeated protocol violations, and when he started the diet again, 
he reported the absence of response. The progressive monthly 
reduction of CH attacks is summarized in Figure 1.
The explorative analysis with an rm-ANOVA model revealed 
that the decrease in attacks for months (dependent variable) 
observed during the diet (within-subject variable: “time,” baseline 
vs. first month vs. second month vs. third month) was significant 
(multivariate test: Wilks’ λ = 0.188, F3,15 = 21.614, p < 0.0001; uni-
variate test, adjusted for the absence of sphericity: F3,51 = 18.392, 
G-G ε = 0.456, p < 0.0001) with a large effect size ηp2 0 520=( ). . 
Post hoc tests (with Bonferroni’s confidence interval adjustment 
for multiple comparisons) of an rm-ANOVA model showed that 
the decreases in attacks for months observed with respect to the 
baseline were significant for the first month (p = 0.003), second 
month (p < 0.0001), and third month (p < 0.0001); the decrease 
in attacks from the first to second month of the diet was also 
significant (p = 0.009).
As for side effects, one patient reported hair-loss and the other 
reported abdominal bloating. Biotin and selenium supplementa-
tion and activated charcoal and probiotics administration suc-
cessfully treated both disorders, respectively. None of the patients 
reported major side effects.
Of the 15 CCH responders, 12 decided to continue the diet over 
the 12 weeks without interruptions. They are still in the follow-up 
phase, undergoing neurological supervision every 3 months and 
laboratory blood tests every 6 months, without a recurrence of 
bouts. The three CCH patients who decided to stop the KD at the 
end of the study period had a recurrence of CH (in one case in 
7 weeks, in another in 10 weeks, and in the last within 6 months). 
Two of them started the diet again, with positive responses, 
whereas the third patient decided not to re-start the diet.
DiscUssiOn
The results of our observations as recorded by their diary and 
blood tests show that MAD is associated with an attack frequency 
reduction in CCH patients, in the absence of any relevant side 
effects.
Only hypotheses can be made about the mechanisms under-
pinning the positive clinical effects we have observed in this study. 
In particular, we paid attention to two possible mechanisms of 
action.
First, KD can induce an increase in brain dopaminergic activ-
ity, as measured in the meso-cortical dopaminergic system of 
mice (6). This datum is relevant to our study because it is known 
that CH is associated with impaired dopaminergic stimulation 
(7). Nonetheless, in a previous report about a drug-resistant 
chronic patient, we observed that treatment with a dopaminergic 
agonist improved CH and reverted his trigeminal neurophysi-
ological abnormalities (8), typical of the active phase of cluster 
(9). Interestingly, similar neurophysiological abnormalities are 
also typical of episodic migraineurs between attacks and, in this 
4Di Lorenzo et al. KD in CH
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kind of patient, KD induced the same neurophysiological changes 
of dopaminergic stimulation that we observed in CH (4), suggest-
ing shared mechanisms between ketogenesis and dopaminergic 
stimulation.
Second, ketone bodies (KBs) can increase the GABAergic 
activity in rat brains (10). As well as in epilepsy, GABA also 
seems to play a protective role in CH. In fact, it is known that the 
sodium salt of the GABA-agonist gamma-hydroxybutyric acid 
(GHB), a drug registered for narcolepsy and alcoholism, is also 
effective in preventing CH attacks (11, 12). It is worth noting that 
the GHB is an isomer (sharing the same molecular formula) of 
beta-hydroxybutyric acid (one of the three KBs), and their simi-
larity could imply that they have very similar biological effects, 
including the direct GABAergic agonism.
About the dietetic intervention, the choice of the MAD 
instead of other KD treatments was due to the observation that 
it is the most adopted ketogenic dietetic regimen in case of adult 
epileptic patients, because of the higher compliance than classic 
KD (13). As reported in the Section “Materials and Methods,” to 
obtain a fine-tuning of diet some patients possibly used a lipid 
supplementation with a commercial product in powder that also 
contains MCT triglycerides and omega-3. The use of this product 
was very limited and extremely variable among patients and diets 
of each patient, thus we must exclude that the CH improvement 
observed in our sample was due to the compound. The choice of 
that product instead of others was made as a result of the lower 
price and the easy way to obtain it (home delivery).
We do not think that the unexpected outstanding positive 
results observed were in any way biased by the fact that all 
patients were referred from a CH support group. In fact, one can 
suppose that they were more motivated than typical neurologists’ 
practice patients as our patients were not previously “keto-
enthusiast” subjects. On the contrary, most of them were patients 
who had lost their confidence in doctors because of previous 
therapeutic failures. We presented them the KD not as a “natural” 
or “alternative” treatment, but as a medical treatment in which the 
diet modification self-produced the drugs (the KBs).
The observational nature of our survey represents the main 
shortcoming of this report. The gold standard in the field of head-
ache research should be a double blind vs. placebo design. However, 
the non-pharmacological nature of the treatment makes it very 
difficult to perform such a study, together with the limited number 
of drug-resistant CCH patients and their urgent need of cure. This 
is in line with other open-label and case series studies performed 
on innovative treatment strategies for drug-resistant CCH patients 
(14, 15). Moreover, the poor reliability of the urine stick in measur-
ing plasmatic KB levels has led us to not perform a correlation with 
clinical outcomes. Further studies can explore this correlation by a 
blood test, the gold standard for this kind of analysis.
We are aware that the impact we observe in this study is large, 
our results need to be taken with caution. In fact, our study 
population consists of treating refractory CCH patients, not 
being under medical care at the time of protocol inclusion. In the 
recent years, several authors already reported a similar effect with 
other off-label treatments, but their data were not confirmed by 
other clinicians nor did this lead to a remarkable change in the 
clinical practice.
cOnclUsiOn
In summary, drug-resistant CH is one of the greatest challenges 
in headache medicine, and new therapeutic options are welcome. 
Our observation suggests that, as well as drug-resistant epilep-
tics and migraineurs, ketogenesis also could help CH patients. 
Although non-conclusive, our preliminary results seem to be 
promising and further studies are recommended.
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